Business Context and Reporting Period
Apogee Therapeutics, Inc. (Nasdaq: APGE) filed a Form 8-K on June 17, 2026, reporting the entry into material definitive agreements with Paragon Therapeutics, Inc. The filing details a strategic partnership focused on the discovery and licensing of monospecific antibodies targeting the interleukin 31 receptor (IL-31R).
Key Financial Metrics and Obligations
This filing does not report historical revenue, profit, cash flow, or liquidity metrics. Instead, it outlines future contingent financial obligations:
- Discovery Fees: Monthly research fees and reimbursement of qualifying costs paid to unaffiliated contract research organizations.
- CMC Activities: Optional fees ranging from $1.3 million to $2.0 million if Paragon performs manufacturing and control activities.
- Milestone Payments: Up to $23.25 million payable upon achievement of specific development, clinical, and regulatory milestones for the first product.
- Initial Milestone: A specific payment of $5.25 million is due upon the first dosing of a human patient in a Phase I trial.
- Royalties: Low-single digit percentage of net sales on a product-by-product and country-by-country basis.
Material Changes and Agreements
The primary material change is the execution of two agreements on June 17, 2026:
- IL-31R Antibody Discovery Agreement: Paragon will generate and characterize monospecific antibody candidates directed at IL-31R. Apogee retains the right to terminate with 30 days' notice.
- IL-31R License Agreement: Paragon granted Apogee an exclusive, worldwide, royalty-bearing, sublicensable license for antibodies discovered under the agreement. Paragon retains non-exclusive rights to develop multispecific antibodies.
Outlook, Risks, and Management Commentary
Development Responsibility: Apogee is solely responsible for the continued development, manufacture, and commercialization of products at its own cost and expense.
Termination Rights: Apogee may terminate the License Agreement in its entirety or on a country-by-country basis at any time for any reason with 60 days' advance written notice. Either party may terminate for material breach or bankruptcy.
Royalty Term: Royalties are due until the later of 12 years after the first commercial sale in a country or the expiration of the last valid patent claim in that country.
Investor Verification Checklist
- Verify the specific definition of "qualifying amounts" for reimbursement under the Discovery Agreement.
- Confirm the detailed schedule of the $23.25 million in milestone payments beyond the initial $5.25 million Phase I dosing payment.
- Assess the impact of the "low-single digit" royalty rate on future gross margins for IL-31R products.
- Review the scope of Paragon's retained non-exclusive rights regarding multispecific antibodies to evaluate potential future competition.
- Monitor the timeline for the first human patient dosing to anticipate the $5.25 million cash outflow.